Bizacumen Inc., Nov 2009, Pages: 286
for initial-stage screening of compounds in drug discovery. Cell/tissue culture involves a diverse assortment of media, sera and reagents. Products essential for sustenance of cells grown in a defined mixture
Global Industry Analysts, Inc., Oct 2010, Pages: 621
™ for Hybridoma Cell Lines
- Biocrystal Presents Opticell
- TAP Unveils CompacT SelecT™
- CellCultureTechnologies Develops Fortified Production Media
9. RECENT INDUSTRY ACTIVITY
- Akron Biotechnology Merges
Business Insights, Sep 2007, Pages: 182
of market drivers, restraints and trends. The production strategies and capacities of leading biopharma companies are assessed, and growth forecasts for microbial fermentations and mammaliancellculture are provided
PharmaVision, Aug 2010, Pages: 183
- Commercial Production
- Manufacturing capabilities
- Mammaliancellculture—still the most widely-used system
- Therapeutic Proteins: Production Challenges
- PTM glycosylation
- PTM misfolded proteins
GBI Research, March 2011, Pages: 109
. The market is expected to grow at a CAGR of 11% for the period 2009-2016, and is expected to reach $11.7 billion by 2016. Advancement in cellculturetechnologies, innovation in the transgenic production system
Global Industry Analysts, Inc., Sep 2008, Pages: 321
: Global Biologics or Biopharmaceutical
Intermediates Market by Leading Technologies and
Services - Microbial Fermentation, MammalianCellCulture, Biopharmaceutical Fill and Finish, Transgenics
Koncept Analytics, May 2010, Pages: 32
of Integrated CMOs
5. Competitive Landscape
5.1 Industry-wide Bio-Pharma Capacity Distribution
5.2 CellCulture Bioreactor Capacity Distribution
6. Company Profiles
6.1 Lonza
Overview
Key Financials
Jain PharmaBiotech, Feb 2012, Pages: 485
to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out
GBI Research, Sep 2010, Pages: 156
.3.3 Overview of MammalianCellCulture Systems 14
3.3.4 Overview of Upstream Bioprocessing 14
3.3.5 Overview of Downstream Bioprocessing 15
3.4 Overview of the Biologics Manufacturing Industry 15
4 Role
John Wiley and Sons Ltd, April 2007, Pages: 696
Cell Bank.
John Davis edited a successful book on basic cellculture. Contributors.
Preface.
List of Abbreviations.
1 The Development of Animal CellProducts: History and Overview (B Griffiths
Frost & Sullivan, March 2006
such as transgenic production of proteins in plants, microorganisms, mammaliancells, and eggs. It also includes an in-depth analysis of new separation technologies for downstream processing and technologies
Business Insights, March 2008, Pages: 165
is the forecast global manufacturing capacity and growth rates for microbial fermentation and mammaliancellculture expression systems over 2006-2011?
- What kind of risks and challenges are inherent
Global Industry Analysts, Inc., Oct 2010, Pages: 228
34
Select Players in the MammalianCellCulture Market 34
Boehringer Ingelheim GMBH (Germany) 34
DSM Pharmaceutical Products (US
Datamonitor, March 2008, Pages: 123
Mammaliancellculture is the most widely used system 27
Emerging technologies 28
Antibody fragments 28
Polyclonal antibodies 29
Antibody mechanism of action and target identification for infectious disease
Informa Healthcare, Jan 2006, Pages: 234
understanding of the biopharmaceutical industry. The report is written to highlight the productiontechnologies and operations that occur in the manufacturing facility.
Chapter 1 provides an overview
Frost & Sullivan, Nov 2003
Drives
Demand
d. Cost Advantage of Biologics Production in Plants Drives Demand
e. Capacity Crunch for Biologics Production in MammalianCellCulture
